Novel agents in renal carcinoma: a reality check

Por Najjar, Yana G., Rini, Brian I.
Publicado em 2012

Renal cell carcinoma clinical management /

Por Campbell, Steven C., Rini, Brian I.
Publicado em c201

Axitinib in Metastatic Renal Cell Carcinoma

Por Mittal, Kriti, Wood, Laura S., Rini, Brian I.
Publicado em 2012

Renal cell carcinoma translational biology, personalized medicine, and novel therapeutic targets /

Por Figlin, Robert A., Rathmell, W. Kimryn., Rini, Brian I.
Publicado em 2012

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Por Zhao, Bo, Wood, Laura S., James, Karen, Rini, Brian I.
Publicado no Case Rep Oncol Med (2015)

Specific immunotherapy in renal cancer: a systematic review

Por Hirbod-Mobarakeh, Armin, Gordan, Hesam Addin, Zahiri, Zahra, Mirshahvalad, Mohammad, Hosseinverdi, Sima, Rini, Brian I., Rezaei, Nima
Publicado no Ther Adv Urol (2016)

Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers

Por Mittal, Kriti, Koon, Henry, Elson, Paul, Triozzi, Pierre, Dowlati, Afshin, Chen, Helen, Borden, Ernest C, Rini, Brian I
Publicado em 2014

GD3, an Over-Expressed, Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated But Not Resting T cells

Por Sa, Gaurisankar, Das, Tanya, Moon, Christina, Hilston, Cynthia M., Rayman, Patricia A., Rini, Brian I., Tannenbaum, Charles S., Finke, James H.
Publicado em 2009

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Por Chittoria, Namita, Haddad, Housam, Elson, Paul, Tannir, Nizar M., Wood, Laura S., Dreicer, Robert, Garcia, Jorge A., Rini, Brian I., Jonasch, Eric
Publicado no BMC Cancer (2016)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Por DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Publicado em 2007

Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform

Por Waitkus, Matthew S., Chandrasekharan, Unni M., Willard, Belinda, Tee, Thomas L., Hsieh, Jason K., Przybycin, Christopher G., Rini, Brian I., DiCorleto, Paul E.
Publicado em 2014

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

Por Porta, Camillo, Gore, Martin E., Rini, Brian I., Escudier, Bernard, Hariharan, Subramanian, Charles, Lorna P., Yang, Liqiang, DeAnnuntis, Liza, Motzer, Robert J.
Publicado no Eur Urol (2015)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Por Rini, Brian I., Cohen, Darrel P., Lu, Dongrui R., Chen, Isan, Hariharan, Subramanian, Gore, Martin E., Figlin, Robert A., Baum, Michael S., Motzer, Robert J.
Publicado em 2011

Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated With Sunitinib

Por Kim, Jenny J., Vaziri, Susan A.J., Rini, Brian I., Elson, Paul, Garcia, Jorge A., Wirka, Robert, Dreicer, Robert, Ganapathi, Mahrukh K., Ganapathi, Ram
Publicado em 2011

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Por Huang, Dan, Ding, Yan, Zhou, Ming, Rini, Brian I., Petillo, David, Qian, Chao-Nan, Kahnoski, Richard, Futreal, P. Andrew, Furge, Kyle A., Teh, Bin Tean
Publicado em 2010

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

Por Diaz-Montero, C Marcela, Mao, Frances J, Barnard, John, Parker, Yvonne, Zamanian-Daryoush, Maryam, Pink, John J, Finke, James H, Rini, Brian I, Lindner, Daniel J
Publicado no Br J Cancer (2016)

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

Por Tomita, Yoshihiko, Fukasawa, Satoshi, Oya, Mototsugu, Uemura, Hirotsugu, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Chen, Ying, Bair, Angel H., Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Publicado no Jpn J Clin Oncol (2016)

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

Por Bose, Anamika, Taylor, Jennifer L., Alber, Sean, Watkins, Simon C., Garcia, Jorge A., Rini, Brian I., Ko, Jennifer S., Cohen, Peter A., Finke, James H., Storkus, Walter J.
Publicado em 2011

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Por Rini, Brian I., Garrett, May, Poland, Bill, Dutcher, Janice P., Rixe, Olivier, Wilding, George, Stadler, Walter M., Pithavala, Yazdi K., Kim, Sinil, Tarazi, Jamal, Motzer, Robert J.
Publicado em 2013

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Por Rini, Brian I., Quinn, David I., Baum, Michael, Wood, Laura S., Tarazi, Jamal, Rosbrook, Brad, Arruda, Lillian Shahied, Cisar, Laura, Roberts, W. Gregory, Kim, Sinil, Motzer, Robert J.
Publicado no Target Oncol (2014)